

HAEMONETICS CORP  
Form 4  
July 01, 2016

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Simon, Christopher

(Last) (First) (Middle)  
400 WOOD ROAD  
(Street)

BRAINTREE, MA 02184

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
HAEMONETICS CORP [HAE]

3. Date of Earliest Transaction  
(Month/Day/Year)  
06/29/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
President & CEO

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	06/29/2016		A	(A) or (D) A	Amount 45,867 (1) Price \$ 0.01	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

## Edgar Filing: HAEMONETICS CORP - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Ar Nu Sh
Non-qualified Stock Option (Right to Buy)	\$ 28.615	06/29/2016		A		196,746 (2)		06/29/2017	06/29/2023	Common Stock	19
Performance Shares	\$ 0	06/29/2016		A		26,210 (3)		03/30/2019	12/31/2019	Common Stock	2
Performance Shares	\$ 0	06/29/2016		A		65,525 (4)		03/30/2019	12/31/2019	Common Stock	6

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Simon, Christopher 400 WOOD ROAD BRAINTREE, MA 02184			President & CEO	

## Signatures

/s/ Alexander Steffan, attorney-in-fact for Mr. Simon 07/01/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Restricted Stock Unit grants which vest 25% per year over 4 years following the grant date. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.
- (2) Grants of right to buy shares of common stock which are exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.  
This grant of Performance Share Units represents a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on measurements of Haemonetics' financial and operational performance. The number of Performance Share Units (and therefore the number of shares payable) will depend on performance during Haemonetics' 2017, 2018 and 2019 fiscal years. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could be up to 150% of the target amount in column 5. The Performance Share Units were granted under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.
- (3) This grant of Performance Share Units represents a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to companies in the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance during a three year period beginning April 3, 2016. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The

## Edgar Filing: HAEMONETICS CORP - Form 4

Performance Share Units were granted under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.